Escherichia coli Nissle 1917 is a probiotic strain with proven efficacy in inducing and maintaining remission of ulcerative colitis.
For Research Use Only. Not intended for use in food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.
Product Information
Product Overview
Escherichia coli Nissle 1917 is a probiotic strain with proven efficacy in inducing and maintaining remission of ulcerative colitis.
Target
Escherichia
Genus
Escherichia
Application
Study and research
Culture Medium
LB Medium
Culture Conditions
37°C; Aerobiotic
Product Format
Freeze-dried
Packaging
Ampoule tube
Storage
-80°C
Shelf Life
6 years
Target Introduction
Introduction
Escherichia coli Nissle (EcN) is a nonpathogenic Gram-negative strain isolated in 1917 by Alfred Nissle and it is the active component of microbial drug used in many gastrointestinal disorder including diarrhea, uncomplicated diverticular disease and IBD, in particular UC.
Alternative Names
Escherichia coli Nissle 1917
FAQsPublished Data Customer Reviews
What are the optimal conditions for culturing Escherichia coli Nissle 1917?
Escherichia coli Nissle 1917 should be cultured at 37°C in aerobic conditions using a nutrient-rich medium such as Luria-Bertani (LB) broth. This strain grows efficiently under these conditions, providing a reliable model for various experimental applications in microbiological research.
How can Escherichia coli Nissle 1917 be used in gut microbiota studies?
Escherichia coli Nissle 1917 is employed in gut microbiota studies to explore its probiotic effects and interactions with the host's gut flora. Researchers administer it to animal models or in vitro systems to study its impact on gut health, immune modulation, and microbial community dynamics.
What are the key genetic features of Escherichia coli Nissle 1917 that make it a valuable research tool?
Escherichia coli Nissle 1917 possesses unique genetic traits, including genes responsible for its probiotic functions, such as adherence to intestinal mucosa and production of antimicrobial compounds. These features make it an important model for studying host-microbe interactions and developing therapeutic strategies.
How should Escherichia coli Nissle 1917 be stored to maintain its viability?
Escherichia coli Nissle 1917 should be stored at -80°C in cryoprotectant solutions like glycerol to maintain its viability. Proper storage conditions ensure the bacteria's stability for long-term use in research, preventing degradation and loss of function.
How can the probiotic effects of Escherichia coli Nissle 1917 be evaluated in experimental studies?
The probiotic effects of Escherichia coli Nissle 1917 can be evaluated through in vivo models, such as rodents, where researchers monitor changes in gut microbiota composition, immune response, and overall health. In vitro studies using intestinal cell lines also provide insights into its beneficial properties.
EcN-Elafin ameliorated DSS-induced chronic colitis in mice
The study focuses on the therapeutic potential of genetically engineered Escherichia coli Nissle 1917 (EcN) expressing Elafin, an inhibitor of neutrophil elastase and proteinase 3, in treating inflammatory bowel disease (IBD). The engineered EcN-Elafin was tested in a mouse model of dextran sodium sulfate (DSS)-induced colitis. The results showed that EcN-Elafin significantly alleviated colitis symptoms, including weight loss, colon shortening, and elevated levels of myeloperoxidase (MPO) and proinflammatory cytokines in colonic tissues. Additionally, EcN-Elafin restored the expression and distribution of the tight junction protein ZO-1, indicating improved intestinal barrier function. In experiments involving Caco-2 cells stimulated with TNF-α, EcN-Elafin downregulated NF-κB signaling, a pathway critical in inflammation. EcN-Elafin also modulated the gut microbiota, restoring microbial diversity and increasing beneficial bacteria while reducing harmful ones. Furthermore, the study highlighted the enhanced production of short-chain fatty acids (SCFAs), particularly butyrate and valerate, in the gut lumen of mice treated with EcN-Elafin. These findings suggest that EcN-Elafin could be a promising therapeutic approach for IBD by enhancing the intestinal barrier, reducing inflammation, and restoring gut microbiota balance.
Teng, Guigen, et al. "Probiotic Escherichia coli Nissle 1917 expressing Elafin protects against inflammation and restores the gut microbiota." Frontiers in microbiology 13 (2022): 819336. Under open access license CC BY 4.0, without modification
.
Outstanding Research Aid Escherichia coli Nissle 1917 from Creative Biolabs significantly improved our gut microbiome studies, providing superior consistency and reliability over other products.
Superior Experimental Results
Using Escherichia coli Nissle 1917 enhanced the accuracy of our microbial interaction research, proving it to be a superior choice compared to similar products.
High-Quality Standards
The high-quality standards of Escherichia coli Nissle 1917 ensured reproducible results in our pharmacokinetic research.
Enhanced Study Efficiency
Incorporating Escherichia coli Nissle 1917 into our studies increased research efficiency, making Creative Biolabs our preferred supplier.
Consistent and Reliable Escherichia coli Nissle 1917 consistently delivered outstanding results in our microbiome research, proving its superiority.
Click the button below to contact us or submit your feedback about this product.
Online Inquiry
For Research Use Only. Not intended for use in food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.
